Int Neurourol J.
2023 Jun;27(2):106-115. 10.5213/inj.2346022.011.
A Randomized, Double-Blind, Placebo-Controlled, Bridging Study to Evaluate the Efficacy and Safety of Vibegron in Treating Korean Patients With Overactive Bladder
- Affiliations
-
- 1Department of Urology, Ewha Womans University Mokdong Hospital, Seoul, Korea
- 2Department of Urology, Seoul National University Bundang Hospital, Seongnam, Korea
- 3Department of Urology, Chonnam National University Medical School, Gwangju, Korea
- 4Department of Urology, Hallym University Sacred Heart Hospital, Anyang, Korea
- 5Department of Urology, Gachon University Gil Medical Center, Incheon, Korea
- 6Department of Urology, Pusan Nation University School of Medicine, Busan, Korea
- 7Department of Urology, Dong-A University College of Medicine, Busan, Korea
- 8Department of Urology, Daegu Fatima Hospital, Daegu, Korea
- 9Department of Urology, College of Medicine, Chungnam National University, Daejeon, Korea
- 10Department of Urology, College of Medicine, The Catholic University of Korea, Seoul, Korea
- 11Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- 12Department of Urology, Asan Medical Center, University of Ulsan, College of Medicine, Seoul, Korea
- KMID: 2543281
- DOI: http://doi.org/10.5213/inj.2346022.011
Abstract
- Purpose
Vibegron, a novel, potent β3 agonist, has been approved for clinical use in overactive bladder (OAB) treatment in Japan and the Unites States. We performed a bridging study to investigate the efficacy and safety of a daily 50-mg vibegron (code name JLP-2002) dose in Korean patients with OAB.
Methods
A multicenter, randomized, double-blind, placebo-controlled study was conducted from September 2020 to August 2021. Adult patients with OAB with a symptom duration of more than 6 months entered a 2-week placebo run-in phase. Eligibility was assessed at the end of this phase and selected patients entered a double-blind treatment phase after 1:1 randomization to either the placebo or vibegron (50 mg) group. The study drug was administered once daily for 12 weeks and follow-up visits were scheduled at weeks 4, 8, and 12. The primary endpoint was the change in mean daily micturition at the end of treatment. The secondary endpoints included changes in OAB symptoms (daily micturition, nocturia, urgency, urgency incontinence, and incontinence episodes, and mean voided volume per micturition) and safety. A constrained longitudinal data model was used for statistical analysis.
Results
Patients who took daily vibegron had significant improvements over the placebo group in both primary and secondary endpoints, except for daily nocturia episodes. The proportions of patients with normalized micturition and resolution of urgency incontinence and incontinence episodes were significantly higher in vibegron group than in the placebo. Vibegron also improved the patients’ quality of life with higher satisfaction rates. The incidence of adverse events in the vibegron and placebo groups was similar with no serious, unexpected adverse drug reactions. No abnormality in electrocardiographs was observed as well as no significant increase in postvoid residual volume.
Conclusions
Once daily vibegron (50 mg) for 12 weeks was effective, safe, and well-tolerated in Korean patients with OAB.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Adjuvant Sertraline Treallnent for Chronic Schizophrenia :A Randomized, Double Blind, Placeho-Controlled Study
- A Six-Week, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Hypotensive Efficacy and Safety of 2%Dorzolamide vs Placebo Ophthalmic Solution
- Meta-Analysis of the Efficacy and Safety of Mirabegron Add-On Therapy to Solifenacin for Overactive Bladder
- The Efficacy of Terazosin in the Treatment of Benign Prostatic Hyperplasia: A Randomized, Placebo-controlled Double Blind Study
- Effects of cetirizine in dogs with chronic atopic dermatitis: a randomized, double blind, placebo-controlled trial
